scholarly journals Retinol-binding protein 4 is associated with insulin resistance, but appears unsuited for metabolic screening in women with polycystic ovary syndrome.

2008 ◽  
Vol 158 (4) ◽  
pp. 517-523 ◽  
Author(s):  
Matthias Möhlig ◽  
Martin O Weickert ◽  
Elham Ghadamgahi ◽  
Ayman M Arafat ◽  
Joachim Spranger ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Polycystic Ovary Syndrome ◽  
Body Mass ◽  
Polycystic Ovary ◽  
Binding Protein ◽  
Retinol Binding Protein ◽  
Ovary Syndrome ◽  
Retinol Binding Protein 4 ◽  
17Β Estradiol ◽  
The Impact

ObjectiveAdiposity, insulin resistance (IR), and hyperandrogenism are features of polycystic ovary syndrome (PCOS). Retinol-binding protein 4 (RBP4) secreted from adipose and liver tissues has been linked to IR. The impact of RBP4 on IR in PCOS and its usability to identify women with metabolic syndrome (MS) or impaired glucose tolerance ((IGT) or diabetes) were investigated.DesignPlasma RBP4 was determined in 115 consecutive PCOS women. Associations with IR, body composition, and hyperandrogenemia were investigated by correlation and multiple linear regression analyses in 110 non-diabetics. Receiver operating characteristic curve analysis was used to evaluate RBP4 as a parameter for identifying MS and IGT or diabetes.ResultsRBP4 increased over tertiles of IR (P=0.009). RBP4 correlated with HOMA %S (R=−0.286, P= 0.002), waist-to-hip ratio (WHR) (R=0.233, P=0.034), and dual energy X-ray absorptiometry (DEXA)-lean body mass (R=0.282, P=0.016) but not with body mass index (BMI), DEXA-total or -trunk fat mass, hsCRP, free testosterone, DHEAS, androstenedione, and 17β-estradiol. Adjusted for age, BMI, smoking, and IGT, the association between RBP4 and HOMA %S remained significant (P=0.032). RBP4 explained 4.6% of the variation in HOMA %S. RBP4 was higher in MS and IGT or diabetes, but its ability to identify these women was low (area under the curve, AUC=0.631, P=0.041 or AUC=0.660, P=0.016).ConclusionsIn PCOS, RBP4 has a small independent impact on IR. It is not correlated with hyperandrogenemia, 17β-estradiol, other adrenal steroids, or with markers of adiposity in general. Furthermore, RBP4 does not appear suitable for screening MS or impaired glucose metabolism (IGT or diabetes).

scholarly journals Retinol-Binding Protein 4 and Insulin Resistance in Polycystic Ovary Syndrome

Diabetes Care ◽  
2008 ◽  
Vol 31 (7) ◽  
pp. 1427-1432 ◽  
Author(s):  
S. K. Hutchison ◽  
C. Harrison ◽  
N. Stepto ◽  
C. Meyer ◽  
H. J. Teede
Keyword(s):  
Insulin Resistance ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Binding Protein ◽  
Retinol Binding Protein ◽  
Ovary Syndrome ◽  
Retinol Binding Protein 4

scholarly journals Serum retinol-binding protein 4 levels in polycystic ovary syndrome

2019 ◽  
Vol 8 (6) ◽  
pp. 709-717
Author(s):  
Shilpa Lingaiah ◽  
Laure Morin-Papunen ◽  
Terhi Piltonen ◽  
Inger Sundström-Poromaa ◽  
Elisabet Stener-Victorin ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Binding Protein ◽  
Serum Levels ◽  
Retinol Binding Protein ◽  
Enzyme Linked Immunosorbent Assay ◽  
Serum Retinol ◽  
Ovary Syndrome ◽  
Retinol Binding Protein 4

Objective Serum levels of retinol-binding protein 4 (RBP4), an adipokine thought to affect systemic insulin sensitivity, were compared between women with polycystic ovary syndrome (PCOS) and non-PCOS controls to evaluate the association of RBP4 with clinical, hormonal and metabolic parameters of PCOS. Subjects and methods Serum RBP4 levels were analysed in 278 women with PCOS (age range 18–57 years) and 191 non-PCOS controls (age 20–53 years) by enzyme-linked immunosorbent assay. Results Serum levels of RBP4 were increased in women with PCOS compared with control women in the whole population (45.1 ± 24.0 (s.d.) vs 33.5 ± 18.3 mg/L, P < 0.001). Age-stratified analysis showed that serum RBP4 levels were increased in women with PCOS aged ≤30 years compared with controls (47.7 ± 23.5 vs 27.1 ± 10.4 mg/L, P < 0.001), whereas no significant differences were seen in the other age groups. No significant correlations of RBP4 were seen with either steroids or indices of insulin resistance. Conclusions Although serum RBP4 levels were increased in younger women with PCOS compared with age-matched non-PCOS controls, RBP4 does not seem to be a good marker of insulin resistance or other metabolic derangements in women with PCOS.

scholarly journals Retinol-binding protein 4 levels are elevated in polycystic ovary syndrome women with obesity and impaired glucose metabolism

2007 ◽  
Vol 157 (2) ◽  
pp. 201-207 ◽  
Author(s):  
Susanne Hahn ◽  
Manuel Backhaus ◽  
Martina Broecker-Preuss ◽  
Susanne Tan ◽  
Tiina Dietz ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Glucose Metabolism ◽  
Polycystic Ovary Syndrome ◽  
Body Fat ◽  
Polycystic Ovary ◽  
Retinol Binding Protein ◽  
Healthy Controls ◽  
Impaired Glucose Metabolism ◽  
Ovary Syndrome ◽  
Retinol Binding Protein 4

Objective: Insulin resistance and obesity are common features of the polycystic ovary syndrome (PCOS). Retinol-binding protein 4 (RBP4), a new fat-derived adipokine, has been described to be elevated in obesity and type 2 diabetes. The aim of the present study was to investigate whether serum RBP4 levels are correlated with metabolic parameters, indices of insulin resistance, and endocrine variables in German PCOS women. Design: We assessed the correlation between metabolic and endocrine parameters with RBP4 levels in 200 PCOS patients and 64 healthy controls. Methods: Serum RBP4 was measured by enzyme-linked immunosorbent assay (Immundiagnostik AG, Bensheim, Germany). In addition, anthropometric variables, clinical signs of hyperandrogenism, and body fat were evaluated, and a glucose tolerance test was performed to assess parameters of insulin resistance and glucose metabolism. Results: Taking the entire PCOS cohort, RBP4 levels were positively correlated with body mass index (BMI), body fat, waist circumference, fasting glucose, and area under the curve for glucose (all P<0.05), but not with indices of insulin resistance. On the other hand, PCOS women with impaired glucose metabolism had higher RBP4 levels than PCOS women with normal glucose metabolism (median 30.6, range 23.3–73.9 versus median 26.3, range 6.4–61.4, P<0.05). Furthermore, no differences were found in RBP4 levels between lean PCOS women and BMI-matched healthy controls. Conclusion: In German PCOS women, serum RBP4 levels are associated with obesity and parameters of glucose metabolism but not with PCOS per se.

Sign in / Sign up

Export Citation Format

Share Document